AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT02725593
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria
Completed
- Conditions
- Oncology & Epidemiology & Lung Cancer
- Interventions
- Other: NIS observational stud
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 897
- Registration Number
- NCT02725892
- Locations
- 🇩🇿
Research Site, Oran, Algeria
An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT02722239
- Locations
- 🇷🇺
Research Site, Moscow, Russian Federation
Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02719132
A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 104
- Registration Number
- NCT02712372
Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment
Completed
- Conditions
- Bladder CancerBreast Cancer
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2133575
- Registration Number
- NCT02695121
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Acute Liver Injury in Patients on Dapagliflozin
Completed
- Conditions
- Acute Liver Injury
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 424091
- Registration Number
- NCT02695095
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Complications of UTI in Patients on Dapagliflozin
Completed
- Conditions
- Severe Complications of Urinary Tract Infections
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 683380
- Registration Number
- NCT02695173
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
Completed
- Conditions
- Acute Kidney Injury
- First Posted Date
- 2016-03-01
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 539310
- Registration Number
- NCT02695082
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes MellitusInadequate Glycaemic Control
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2018-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 905
- Registration Number
- NCT02681094
- Locations
- 🇷🇺
Research Site, Vladikavkaz, Russian Federation